Literature DB >> 18923403

Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Han-Ting Zhang1, Lisa R Whisler, Ying Huang, Yang Xiang, James M O'Donnell.   

Abstract

The antidepressant desipramine inhibits the reuptake of norepinephrine (NE), leading to activation of both pre- and postsynaptic adrenergic receptors, including alpha-1, alpha-2, beta-1, and beta-2 subtypes. However, it is not clear which adrenergic receptors are involved in mediating its antidepressant effects. Treatment of mice with desipramine (20 mg/kg, i.p.) produced an antidepressant-like effect, as evidenced by decreased immobility in the forced-swim test; this was antagonized by pretreatment with the alpha-2 adrenergic antagonist idazoxan (0.1-2.5 mg/kg, i.p.). Similarly, idazoxan, administered peripherally (0.5-2.5 mg/kg, i.p.) or centrally (1-10 microg, i.c.v.), antagonized the antidepressant-like effect of desipramine in rats responding under a differential-reinforcement-of-low-rate (DRL) 72-s schedule, ie, decreased response rate and increased reinforcement rate. By contrast, pretreatment with the beta-adrenergic antagonists propranolol and CGP-12177 or the alpha-1 adrenergic antagonist prazosin did not alter the antidepressant-like effect of desipramine on DRL behavior. The lack of involvement of beta-adrenergic receptors in mediating the behavioral effects of desipramine was confirmed using knockout lines. In the forced-swim test, the desipramine-induced decrease in immobility was not altered in mice deficient in beta-1, beta-2, or both beta-1 and beta-2 adrenergic receptors. In addition, desipramine (3-30 mg/kg) produced an antidepressant-like effect on behavior under a DRL 36-s schedule in mice deficient in both beta-1 and beta-2 adrenergic receptors. As antagonism of presynaptic alpha-2 adrenergic receptors facilitates NE release, which potentiates the effects of desipramine, the present results suggest that postsynaptic alpha-2 adrenergic receptors play an important role in its antidepressant effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923403      PMCID: PMC2727683          DOI: 10.1038/npp.2008.184

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  76 in total

1.  Differential modulation of alpha2-adrenoceptor subtypes in rat kidney by chronic desipramine treatment.

Authors:  L F Callado; A M Gabilondo; J J Meana
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

2.  Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.

Authors:  Liliane J Dableh; Kiran Yashpal; Joseph Rochford; James L Henry
Journal:  Eur J Pharmacol       Date:  2004-12-28       Impact factor: 4.432

3.  Targeted disruption of the beta2 adrenergic receptor gene.

Authors:  A J Chruscinski; D K Rohrer; E Schauble; K H Desai; D Bernstein; B K Kobilka
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

4.  Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors.

Authors:  D K Rohrer; A Chruscinski; E H Schauble; D Bernstein; B K Kobilka
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

5.  Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade.

Authors:  L Linnér; L Arborelius; G G Nomikos; L Bertilsson; T H Svensson
Journal:  Biol Psychiatry       Date:  1999-09-15       Impact factor: 13.382

6.  Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo.

Authors:  S Esteban; J Lladó; A Sastre-Coll; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-08       Impact factor: 3.000

7.  Effects of intrathecal 6-hydroxydopamine, alpha1 and alpha2 adrenergic receptor antagonists on antinociception of propofol in mice.

Authors:  Zhi-Jun Ge; Yin-Ming Zeng; Yong-Fei Tan
Journal:  Acta Pharmacol Sin       Date:  2005-02       Impact factor: 6.150

8.  Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels.

Authors:  J Sallinen; A Haapalinna; E MacDonald; T Viitamaa; J Lähdesmäki; E Rybnikova; M Pelto-Huikko; B K Kobilka; M Scheinin
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

Review 9.  Imidazoline receptors and human brain disorders.

Authors:  J A García-Sevilla; P V Escribá; J Guimón
Journal:  Ann N Y Acad Sci       Date:  1999-06-21       Impact factor: 5.691

10.  Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine.

Authors:  M Maes; A Van Gastel; L Delmeire; H Y Meltzer
Journal:  Biol Psychiatry       Date:  1999-02-01       Impact factor: 13.382

View more
  23 in total

1.  α₂- and β-adrenoceptors involvement in nortriptyline modulation of auditory sustained attention and impulsivity.

Authors:  Swagata Roychowdhury; Zulma Peña-Contreras; Jason Tam; Amulya Yadlapalli; Lu Dinh; Justin Andrew Nichols; Debarshi Basu; Marco Atzori
Journal:  Psychopharmacology (Berl)       Date:  2012-01-21       Impact factor: 4.530

2.  Association study of three single-nucleotide polymorphisms in the cyclic adenosine monophosphate response element binding 1 gene and major depressive disorder.

Authors:  Yange Wei; Shufang Bu; Xican Liu; Hengfen Li
Journal:  Exp Ther Med       Date:  2015-04-03       Impact factor: 2.447

3.  Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin.

Authors:  Christopher Cottingham; Xiaohua Li; Qin Wang
Journal:  Neuropharmacology       Date:  2012-02-19       Impact factor: 5.250

4.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

5.  Changes in behavior and ultrasonic vocalizations during antidepressant treatment in the maternally separated Wistar-Kyoto rat model of depression.

Authors:  P J van Zyl; J J Dimatelis; V A Russell
Journal:  Metab Brain Dis       Date:  2013-12-12       Impact factor: 3.584

6.  Changes in postnatal norepinephrine alter alpha-2 adrenergic receptor development.

Authors:  J D Sanders; H K Happe; D B Bylund; L C Murrin
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

7.  Modulation of Monoaminergic Systems by Antidepressants in the Frontal Cortex of Rats After Chronic Mild Stress Exposure.

Authors:  David Martín-Hernández; Marta P Pereira; Hiram Tendilla-Beltrán; José L M Madrigal; Borja García-Bueno; Juan C Leza; Javier R Caso
Journal:  Mol Neurobiol       Date:  2019-05-03       Impact factor: 5.590

8.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

Review 9.  α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Authors:  Christopher Cottingham; Qin Wang
Journal:  Neurosci Biobehav Rev       Date:  2012-08-13       Impact factor: 8.989

10.  RGS9-2--controlled adaptations in the striatum determine the onset of action and efficacy of antidepressants in neuropathic pain states.

Authors:  Vasiliki Mitsi; Dimitra Terzi; Immanuel Purushothaman; Lefteris Manouras; Sevasti Gaspari; Rachael L Neve; Maria Stratinaki; Jian Feng; Li Shen; Venetia Zachariou
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.